𝔖 Bobbio Scriptorium
✦   LIBER   ✦

What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?

✍ Scribed by István Molnár; Bayard L. Powell

Book ID
107540170
Publisher
Current Science Inc.
Year
2007
Tongue
English
Weight
174 KB
Volume
2
Category
Article
ISSN
1558-8211

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemtuzumab ozogamicin in the treatment o
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
✍ Francis Giles; Elihu Estey; Susan O'Brien 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB 👁 2 views

## Abstract Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti‐CD33 antibody (hP67.6) linked to N‐acetyl‐γ calicheamicin 1,2‐dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration

Possible association between Budd-Chiari
Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia
✍ Mevlüt Kurt; Ali Shorbagi; Kadri Altundag; Tamer Elkiran; Ibrahim Güllü; Emin Ka 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Abstract Gemtuzumab ozogamicin (GO; CMA‐676; Mylotarg™) is a chemotherapeutic agent approved for the treatment of CD33‐positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno‐occlusive disease has been reported to develop as a late complication